Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021)
Candel Therapeutics (CADL) reported Preferred Stock Liabilities of $22.5 million for Q2 2021, down 15.29% on a YoY basis from $26.6 million in Q2 2020, and little changed sequentially from $22.5 million in Q1 2021.
Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Candel Therapeutics (CADL) has 2 years of Preferred Stock Liabilities data on file, last reported at $22.5 million in Q2 2021.
- For the quarter ending Q2 2021, Preferred Stock Liabilities fell 15.29% year-over-year to $22.5 million; the trailing twelve-month figure through Jun 2021 stood at $22.5 million (down 15.29% YoY), and the FY2020 full-year result was $22.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $22.5 million in Q2 2021, from $22.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $26.6 million in Q2 2020 to a low of $22.5 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Candel Therapeutics | 542.51 Mn | 542.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 22.50 Mn |
| Mar 31, 2021 | 22.50 Mn |
| Dec 31, 2020 | 22.50 Mn |
| Sep 30, 2020 | 26.56 Mn |
| Jun 30, 2020 | 26.56 Mn |